An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a study, publishing in the journal Clinical Cancer Research online Aug. 8, shows.
Medical Xpress – latest medical and health news stories
